These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38583495)

  • 1. Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma.
    Wang Q; Ji X; Sun J; Zhang A; Jia J; Zhang T; Li W; Duan X
    Int J Radiat Oncol Biol Phys; 2024 Dec; 120(5):1363-1376. PubMed ID: 38583495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of PD-1 inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a retrospective study.
    Ding Z; Fang G; Tang Y; Zeng Y
    Sci Rep; 2024 Jun; 14(1):14334. PubMed ID: 38906915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
    Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
    Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study.
    Chen S; Xu B; Wu Z; Wang P; Yu W; Liu Z; Huang X; Wu Y; Li T; Guo W
    BMC Cancer; 2021 Oct; 21(1):1126. PubMed ID: 34670506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma.
    Li S; Mei J; Zhao R; Zhou J; Wang Q; Lu L; Li J; Zheng L; Wei W; Guo R
    Front Immunol; 2024; 15():1491857. PubMed ID: 39507533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiotherapy versus lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity matching score analysis.
    Ji X; Zhang A; Duan X; Wang Q
    Radiat Oncol; 2024 Oct; 19(1):143. PubMed ID: 39394613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.
    Fu Z; Li X; Zhong J; Chen X; Cao K; Ding N; Liu L; Zhang X; Zhai J; Qu Z
    Hepatol Int; 2021 Jun; 15(3):663-675. PubMed ID: 33877527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Retrospective, Multicenter Study.
    Ou X; Wu J; Wu J; Fu Y; Zeng Z; Li S; Li Y; Liu D; Li H; Li B; Zhou J; Zhuang S; Cheng S; Zhang Z; Wang K; Qu S; Yan M
    Cancer Res Treat; 2024 Oct; 56(4):1207-1218. PubMed ID: 38697847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of Radiofrequency ablation combined with Lenvatinib plus Sintilimab in Unresectable Hepatocellular Carcinoma: a real-world study.
    Wang X; Sun X; Lei Y; Fang L; Wang Y; Feng K; Xia F
    BMC Cancer; 2024 Aug; 24(1):1036. PubMed ID: 39174912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA.
    Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
    Future Oncol; 2021 Jul; 17(21):2759-2768. PubMed ID: 33832339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.
    Xu YJ; Lai ZC; He MK; Bu XY; Chen HW; Zhou YM; Xu L; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M; Li QJ
    Technol Cancer Res Treat; 2021; 20():15330338211063848. PubMed ID: 34898313
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of stereotactic body radiotherapy with and without lenvatinib for advanced hepatocellular carcinoma: a propensity score analysis.
    Wang Q; Ji X; Sun J; Li W; Duan X; Zhang A
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7441-7452. PubMed ID: 36952005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma.
    Wang YY; Yang X; Wang YC; Long JY; Sun HS; Li YR; Xun ZY; Zhang N; Xue JN; Ning C; Zhang JW; Zhu CP; Zhang LH; Yang XB; Zhao HT
    World J Gastroenterol; 2023 Mar; 29(10):1614-1626. PubMed ID: 36970591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma.
    Xin Y; Zhang X; Liu N; Peng G; Huang X; Cao X; Zhou X; Li X
    Hepatol Int; 2023 Jun; 17(3):753-764. PubMed ID: 37038024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
    Tang Z; Bai T; Wei T; Wang X; Chen J; Ye J; Li S; Wei M; Li X; Lin Y; Tang J; Li L; Wu F
    BMC Cancer; 2024 Jun; 24(1):717. PubMed ID: 38862932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of DEB-TACE in combination with lenvatinib and camrelizumab for the treatment of unresectable hepatocellular carcinoma (uHCC): a two-centre retrospective study.
    Xuexian Z; Ruidong W; Yuhan D; Qingwei L; Feng X; Hong R; Jun Z; Wei L
    Front Immunol; 2024; 15():1422784. PubMed ID: 39502690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
    Chen S; Wu Z; Shi F; Mai Q; Wang L; Wang F; Zhuang W; Chen X; Chen H; Xu B; Lai J; Guo W
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):2115-2125. PubMed ID: 34453221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficiency and Stability of Transarterial Chemoembolization Combined With or Without Lenvatinib for Unresectable Hepatocellular Carcinoma.
    Zong Z; Tang R; Li M; Xiong X; Li D; Fan J; Ye W; Xue C
    Turk J Gastroenterol; 2024 Mar; 35(3):212-222. PubMed ID: 39128062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study.
    Meng L; Li H; Ji Y; Yu P; Wang Z; Cao L; Shi B; Shao Y; Yan J; Gao Y; Zhu Z
    Cancer Immunol Immunother; 2024 Nov; 74(1):13. PubMed ID: 39499356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study.
    Huang J; Wang ZG; Tao QF; Yang Y; Yuan SX; Gu FM; Liu H; Pan ZY; Jiang BG; Lau WY; Zhou WP
    Front Immunol; 2023; 14():1198562. PubMed ID: 37483609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.